ID   SCRB2_HUMAN             Reviewed;         478 AA.
AC   Q14108; B4DKD8; E7EM68; Q53Y63;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   28-JUN-2023, entry version 206.
DE   RecName: Full=Lysosome membrane protein 2;
DE   AltName: Full=85 kDa lysosomal membrane sialoglycoprotein;
DE            Short=LGP85;
DE   AltName: Full=CD36 antigen-like 2;
DE   AltName: Full=Lysosome membrane protein II;
DE            Short=LIMP II;
DE   AltName: Full=Scavenger receptor class B member 2;
DE   AltName: CD_antigen=CD36;
GN   Name=SCARB2; Synonyms=CD36L2, LIMP2, LIMPII;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1374238; DOI=10.1016/0006-291x(92)90632-u;
RA   Fujita H., Takata Y., Kono A., Tanaka Y., Takahashi T., Himeno M., Kato K.;
RT   "Isolation and sequencing of a cDNA clone encoding the 85 kDa human
RT   lysosomal sialoglycoprotein (hLGP85) in human metastatic pancreas islet
RT   tumor cells.";
RL   Biochem. Biophys. Res. Commun. 184:604-611(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7539776; DOI=10.1016/0888-7543(95)80114-2;
RA   Calvo D., Dopazo J., Vega M.A.;
RT   "The CD36, CLA-1 (CD36L1), and LIMPII (CD36L2) gene family: cellular
RT   distribution, chromosomal location, and genetic evolution.";
RL   Genomics 25:100-106(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Cerebellum, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   MUTAGENESIS OF LEU-475; ILE-476; ARG-477 AND THR-478, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=7509809; DOI=10.1016/s0021-9258(17)37418-5;
RA   Sandoval I.V., Arredondo J.J., Alcalde J., Gonzalez Noriega A.,
RA   Vandekerckhove J., Jimenez M.A., Rico M.;
RT   "The residues Leu(Ile)475-Ile(Leu, Val, Ala)476, contained in the extended
RT   carboxyl cytoplasmic tail, are critical for targeting of the resident
RT   lysosomal membrane protein LIMP II to lysosomes.";
RL   J. Biol. Chem. 269:6622-6631(1994).
RN   [9]
RP   MASS SPECTROMETRY.
RC   TISSUE=Mammary cancer;
RX   PubMed=11840567;
RX   DOI=10.1002/1615-9861(200202)2:2<212::aid-prot212>3.0.co;2-h;
RA   Harris R.A., Yang A., Stein R.C., Lucy K., Brusten L., Herath A.,
RA   Parekh R., Waterfield M.D., O'Hare M.J., Neville M.A., Page M.J.,
RA   Zvelebil M.J.;
RT   "Cluster analysis of an extensive human breast cancer cell line protein
RT   expression map database.";
RL   Proteomics 2:212-223(2002).
RN   [10]
RP   GLYCOSYLATION AT ASN-249 AND ASN-412.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, REGION, AND INTERACTION WITH GBA1.
RX   PubMed=18022370; DOI=10.1016/j.cell.2007.10.018;
RA   Reczek D., Schwake M., Schroder J., Hughes H., Blanz J., Jin X.,
RA   Brondyk W., Van Patten S., Edmunds T., Saftig P.;
RT   "LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent
RT   targeting of beta-glucocerebrosidase.";
RL   Cell 131:770-783(2007).
RN   [12]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Placenta;
RX   PubMed=17897319; DOI=10.1111/j.1600-0854.2007.00643.x;
RA   Schroeder B., Wrocklage C., Pan C., Jaeger R., Koesters B., Schaefer H.,
RA   Elsaesser H.-P., Mann M., Hasilik A.;
RT   "Integral and associated lysosomal membrane proteins.";
RL   Traffic 8:1676-1686(2007).
RN   [13]
RP   INVOLVEMENT IN EPM4.
RX   PubMed=18308289; DOI=10.1016/j.ajhg.2007.12.019;
RA   Berkovic S.F., Dibbens L.M., Oshlack A., Silver J.D., Katerelos M.,
RA   Vears D.F., Luellmann-Rauch R., Blanz J., Zhang K.W., Stankovich J.,
RA   Kalnins R.M., Dowling J.P., Andermann E., Andermann F., Faldini E.,
RA   D'Hooge R., Vadlamudi L., Macdonell R.A., Hodgson B.L., Bayly M.A.,
RA   Savige J., Mulley J.C., Smyth G.K., Power D.A., Saftig P., Bahlo M.;
RT   "Array-based gene discovery with three unrelated subjects shows
RT   SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and
RT   glomerulosclerosis.";
RL   Am. J. Hum. Genet. 82:673-684(2008).
RN   [14]
RP   INVOLVEMENT IN EPM4.
RX   PubMed=18424452; DOI=10.1093/hmg/ddn124;
RA   Balreira A., Gaspar P., Caiola D., Chaves J., Beirao I., Lima J.L.,
RA   Azevedo J.E., Miranda M.C.;
RT   "A nonsense mutation in the LIMP-2 gene associated with progressive
RT   myoclonic epilepsy and nephrotic syndrome.";
RL   Hum. Mol. Genet. 17:2238-2243(2008).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-45; ASN-68; ASN-105; ASN-206;
RP   ASN-249; ASN-304 AND ASN-325.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [16]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HOST ENTEROVIRUS 71
RP   CAPSID PROTEIN VP1 AND VP2 (MICROBIAL INFECTION).
RX   PubMed=19543282; DOI=10.1038/nm.1992;
RA   Yamayoshi S., Yamashita Y., Li J., Hanagata N., Minowa T., Takemura T.,
RA   Koike S.;
RT   "Scavenger receptor B2 is a cellular receptor for enterovirus 71.";
RL   Nat. Med. 15:798-801(2009).
RN   [17]
RP   INVOLVEMENT IN EPM4.
RX   PubMed=21670406; DOI=10.1001/archneurol.2011.120;
RA   Dibbens L.M., Karakis I., Bayly M.A., Costello D.J., Cole A.J.,
RA   Berkovic S.F.;
RT   "Mutation of SCARB2 in a patient with progressive myoclonus epilepsy and
RT   demyelinating peripheral neuropathy.";
RL   Arch. Neurol. 68:812-813(2011).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   INVOLVEMENT IN GAUCHER DISEASE AS MODIFIER GENE, AND VARIANT GLY-471.
RX   PubMed=21796727; DOI=10.1002/humu.21566;
RA   Velayati A., DePaolo J., Gupta N., Choi J.H., Moaven N., Westbroek W.,
RA   Goker-Alpan O., Goldin E., Stubblefield B.K., Kolodny E., Tayebi N.,
RA   Sidransky E.;
RT   "A mutation in SCARB2 is a modifier in Gaucher disease.";
RL   Hum. Mutat. 32:1232-1238(2011).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [22] {ECO:0007744|PDB:6I2K}
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HOST ENTEROVIRUS 71
RP   CAPSID PROTEIN VP1 AND VP2 (MICROBIAL INFECTION).
RX   PubMed=30531980; DOI=10.1038/s41564-018-0319-z;
RA   Zhou D., Zhao Y., Kotecha A., Fry E.E., Kelly J.T., Wang X., Rao Z.,
RA   Rowlands D.J., Ren J., Stuart D.I.;
RT   "Unexpected mode of engagement between enterovirus 71 and its receptor
RT   SCARB2.";
RL   Nat. Microbiol. 4:414-419(2019).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 35-430, DISULFIDE BOND,
RP   GLYCOSYLATION AT ASN-45; ASN-68; ASN-206; ASN-224; ASN-249; ASN-304;
RP   ASN-325 AND ASN-412, AND INTERACTION WITH GBA1.
RX   PubMed=24162852; DOI=10.1038/nature12684;
RA   Neculai D., Schwake M., Ravichandran M., Zunke F., Collins R.F., Peters J.,
RA   Neculai M., Plumb J., Loppnau P., Pizarro J.C., Seitova A., Trimble W.S.,
RA   Saftig P., Grinstein S., Dhe-Paganon S.;
RT   "Structure of LIMP-2 provides functional insights with implications for SR-
RT   BI and CD36.";
RL   Nature 504:172-176(2013).
RN   [24]
RP   VARIANT EPM4 ASN-363.
RX   PubMed=19454373; DOI=10.1016/j.ymgme.2009.04.011;
RA   Dardis A., Filocamo M., Grossi S., Ciana G., Franceschetti S.,
RA   Dominissini S., Rubboli G., Di Rocco M., Bembi B.;
RT   "Biochemical and molecular findings in a patient with myoclonic epilepsy
RT   due to a mistarget of the beta-glucosidase enzyme.";
RL   Mol. Genet. Metab. 97:309-311(2009).
CC   -!- FUNCTION: Acts as a lysosomal receptor for glucosylceramidase (GBA1)
CC       targeting. {ECO:0000269|PubMed:18022370}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for enterovirus 71.
CC       {ECO:0000269|PubMed:19543282, ECO:0000269|PubMed:30531980}.
CC   -!- SUBUNIT: Interacts with GBA1. {ECO:0000269|PubMed:18022370,
CC       ECO:0000269|PubMed:24162852}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with enterovirus 71 capsid
CC       proteins VP1 and VP2. {ECO:0000269|PubMed:19543282,
CC       ECO:0000269|PubMed:30531980}.
CC   -!- INTERACTION:
CC       Q14108; Q8N6F1-2: CLDN19; NbExp=3; IntAct=EBI-1564650, EBI-12256978;
CC       Q14108; Q9Y282: ERGIC3; NbExp=3; IntAct=EBI-1564650, EBI-781551;
CC       Q14108; O60883: GPR37L1; NbExp=3; IntAct=EBI-1564650, EBI-2927498;
CC       Q14108; Q8TED1: GPX8; NbExp=3; IntAct=EBI-1564650, EBI-11721746;
CC       Q14108; P31937: HIBADH; NbExp=3; IntAct=EBI-1564650, EBI-11427100;
CC       Q14108; Q86VI4: LAPTM4B; NbExp=3; IntAct=EBI-1564650, EBI-3267258;
CC   -!- SUBCELLULAR LOCATION: Lysosome membrane {ECO:0000269|PubMed:17897319,
CC       ECO:0000269|PubMed:18022370, ECO:0000269|PubMed:7509809}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:17897319,
CC       ECO:0000269|PubMed:18022370, ECO:0000269|PubMed:7509809}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q14108-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14108-2; Sequence=VSP_044826;
CC   -!- MASS SPECTROMETRY: Mass=54158.97; Method=MALDI;
CC       Evidence={ECO:0000269|PubMed:11840567};
CC   -!- DISEASE: Epilepsy, progressive myoclonic 4, with or without renal
CC       failure (EPM4) [MIM:254900]: A form of progressive myoclonic epilepsy,
CC       a clinically and genetically heterogeneous group of disorders defined
CC       by the combination of action and reflex myoclonus, other types of
CC       epileptic seizures, and progressive neurodegeneration and
CC       neurocognitive impairment. EPM4 is an autosomal recessive form
CC       associated with renal failure in some cases. Cognitive function is
CC       preserved. {ECO:0000269|PubMed:18308289, ECO:0000269|PubMed:18424452,
CC       ECO:0000269|PubMed:19454373, ECO:0000269|PubMed:21670406}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=Genetic variants in SCARB2 can act as modifier of the
CC       phenotypic expression and severity of Gaucher disease.
CC       {ECO:0000269|PubMed:21796727}.
CC   -!- SIMILARITY: Belongs to the CD36 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D12676; BAA02177.1; -; mRNA.
DR   EMBL; BT006939; AAP35585.1; -; mRNA.
DR   EMBL; AK296519; BAG59150.1; -; mRNA.
DR   EMBL; AK313016; BAG35851.1; -; mRNA.
DR   EMBL; AC034139; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC110795; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471057; EAX05779.1; -; Genomic_DNA.
DR   EMBL; BC021892; AAH21892.1; -; mRNA.
DR   CCDS; CCDS3577.1; -. [Q14108-1]
DR   CCDS; CCDS56335.1; -. [Q14108-2]
DR   PIR; A56525; A56525.
DR   RefSeq; NP_001191184.1; NM_001204255.1. [Q14108-2]
DR   RefSeq; NP_005497.1; NM_005506.3. [Q14108-1]
DR   PDB; 4F7B; X-ray; 3.00 A; A/B/C/D/E/F=35-430.
DR   PDB; 4Q4B; X-ray; 2.82 A; A=28-431.
DR   PDB; 4Q4F; X-ray; 2.80 A; A=28-432.
DR   PDB; 4TVZ; X-ray; 3.01 A; A/B=37-430.
DR   PDB; 4TW0; X-ray; 3.65 A; A/B/C/D=37-429.
DR   PDB; 4TW2; X-ray; 2.89 A; A/B=37-430.
DR   PDB; 5UPH; X-ray; 3.00 A; A/B=28-431.
DR   PDB; 5XBM; X-ray; 3.50 A; C/F=37-430.
DR   PDB; 6I2K; EM; 3.40 A; E=28-432.
DR   PDBsum; 4F7B; -.
DR   PDBsum; 4Q4B; -.
DR   PDBsum; 4Q4F; -.
DR   PDBsum; 4TVZ; -.
DR   PDBsum; 4TW0; -.
DR   PDBsum; 4TW2; -.
DR   PDBsum; 5UPH; -.
DR   PDBsum; 5XBM; -.
DR   PDBsum; 6I2K; -.
DR   AlphaFoldDB; Q14108; -.
DR   SMR; Q14108; -.
DR   BioGRID; 107388; 200.
DR   ELM; Q14108; -.
DR   IntAct; Q14108; 155.
DR   MINT; Q14108; -.
DR   STRING; 9606.ENSP00000264896; -.
DR   TCDB; 9.B.39.1.13; the long chain fatty acid translocase (lcfat) family.
DR   GlyConnect; 1479; 41 N-Linked glycans (7 sites).
DR   GlyCosmos; Q14108; 10 sites, 43 glycans.
DR   GlyGen; Q14108; 11 sites, 45 N-linked glycans (8 sites), 1 O-linked glycan (1 site).
DR   iPTMnet; Q14108; -.
DR   PhosphoSitePlus; Q14108; -.
DR   SwissPalm; Q14108; -.
DR   BioMuta; SCARB2; -.
DR   DMDM; 2498525; -.
DR   CPTAC; CPTAC-127; -.
DR   CPTAC; CPTAC-128; -.
DR   EPD; Q14108; -.
DR   jPOST; Q14108; -.
DR   MassIVE; Q14108; -.
DR   MaxQB; Q14108; -.
DR   PaxDb; Q14108; -.
DR   PeptideAtlas; Q14108; -.
DR   ProteomicsDB; 16872; -.
DR   ProteomicsDB; 59816; -. [Q14108-1]
DR   ABCD; Q14108; 1 sequenced antibody.
DR   Antibodypedia; 3014; 467 antibodies from 38 providers.
DR   DNASU; 950; -.
DR   Ensembl; ENST00000264896.8; ENSP00000264896.2; ENSG00000138760.11. [Q14108-1]
DR   Ensembl; ENST00000452464.6; ENSP00000399154.2; ENSG00000138760.11. [Q14108-2]
DR   GeneID; 950; -.
DR   KEGG; hsa:950; -.
DR   MANE-Select; ENST00000264896.8; ENSP00000264896.2; NM_005506.4; NP_005497.1.
DR   UCSC; uc003hju.3; human. [Q14108-1]
DR   AGR; HGNC:1665; -.
DR   CTD; 950; -.
DR   DisGeNET; 950; -.
DR   GeneCards; SCARB2; -.
DR   GeneReviews; SCARB2; -.
DR   HGNC; HGNC:1665; SCARB2.
DR   HPA; ENSG00000138760; Low tissue specificity.
DR   MalaCards; SCARB2; -.
DR   MIM; 254900; phenotype.
DR   MIM; 602257; gene.
DR   neXtProt; NX_Q14108; -.
DR   OpenTargets; ENSG00000138760; -.
DR   Orphanet; 163696; Action myoclonus-renal failure syndrome.
DR   Orphanet; 77259; Gaucher disease type 1.
DR   Orphanet; 308; Progressive myoclonic epilepsy type 1.
DR   PharmGKB; PA35038; -.
DR   VEuPathDB; HostDB:ENSG00000138760; -.
DR   eggNOG; KOG3776; Eukaryota.
DR   GeneTree; ENSGT00940000153372; -.
DR   HOGENOM; CLU_019853_3_0_1; -.
DR   InParanoid; Q14108; -.
DR   OMA; PPIYMEY; -.
DR   OrthoDB; 315994at2759; -.
DR   PhylomeDB; Q14108; -.
DR   TreeFam; TF317925; -.
DR   PathwayCommons; Q14108; -.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   SignaLink; Q14108; -.
DR   BioGRID-ORCS; 950; 16 hits in 1161 CRISPR screens.
DR   ChiTaRS; SCARB2; human.
DR   GeneWiki; SCARB2; -.
DR   GenomeRNAi; 950; -.
DR   Pharos; Q14108; Tbio.
DR   PRO; PR:Q14108; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q14108; protein.
DR   Bgee; ENSG00000138760; Expressed in inferior vagus X ganglion and 212 other tissues.
DR   ExpressionAtlas; Q14108; baseline and differential.
DR   Genevisible; Q14108; HS.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0030666; C:endocytic vesicle membrane; ISS:ARUK-UCL.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:ARUK-UCL.
DR   GO; GO:0010008; C:endosome membrane; TAS:ARUK-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:ARUK-UCL.
DR   GO; GO:0031902; C:late endosome membrane; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0043202; C:lysosomal lumen; ISS:BHF-UCL.
DR   GO; GO:0005765; C:lysosomal membrane; HDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:ARUK-UCL.
DR   GO; GO:0038024; F:cargo receptor activity; IMP:ARUK-UCL.
DR   GO; GO:0015485; F:cholesterol binding; ISS:ARUK-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0031210; F:phosphatidylcholine binding; ISS:ARUK-UCL.
DR   GO; GO:0001786; F:phosphatidylserine binding; ISS:ARUK-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:ARUK-UCL.
DR   GO; GO:0051087; F:protein-folding chaperone binding; IEA:Ensembl.
DR   GO; GO:0005044; F:scavenger receptor activity; ISS:ARUK-UCL.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; TAS:ARUK-UCL.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0015917; P:aminophospholipid transport; ISS:ARUK-UCL.
DR   GO; GO:0010467; P:gene expression; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; ISS:ARUK-UCL.
DR   GO; GO:0006622; P:protein targeting to lysosome; IMP:BHF-UCL.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; ISS:ARUK-UCL.
DR   GO; GO:0043470; P:regulation of carbohydrate catabolic process; IMP:ARUK-UCL.
DR   GO; GO:1904978; P:regulation of endosome organization; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1905123; P:regulation of glucosylceramidase activity; IBA:GO_Central.
DR   GO; GO:1905671; P:regulation of lysosome organization; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0007605; P:sensory perception of sound; IEA:Ensembl.
DR   InterPro; IPR002159; CD36_fam.
DR   InterPro; IPR005429; LimpII.
DR   PANTHER; PTHR11923:SF92; LYSOSOME MEMBRANE PROTEIN 2; 1.
DR   PANTHER; PTHR11923; SCAVENGER RECEPTOR CLASS B TYPE-1 SR-B1; 1.
DR   Pfam; PF01130; CD36; 1.
DR   PRINTS; PR01609; CD36FAMILY.
DR   PRINTS; PR01611; LIMPII.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Disease variant; Disulfide bond;
KW   Epilepsy; Glycoprotein; Host cell receptor for virus entry;
KW   Host-virus interaction; Lysosome; Membrane; Neurodegeneration; Receptor;
KW   Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN           1..478
FT                   /note="Lysosome membrane protein 2"
FT                   /id="PRO_0000144155"
FT   TOPO_DOM        1..4
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        5..27
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        28..433
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        434..459
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        460..478
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          155..191
FT                   /note="Important for interaction with GBA1"
FT   CARBOHYD        45
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:24162852"
FT   CARBOHYD        68
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:24162852"
FT   CARBOHYD        105
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        206
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:24162852"
FT   CARBOHYD        224
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:24162852"
FT   CARBOHYD        249
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:24162852"
FT   CARBOHYD        304
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:24162852"
FT   CARBOHYD        325
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:24162852"
FT   CARBOHYD        412
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:24162852"
FT   CARBOHYD        430
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        274..329
FT                   /evidence="ECO:0000269|PubMed:24162852"
FT   DISULFID        312..318
FT                   /evidence="ECO:0000269|PubMed:24162852"
FT   VAR_SEQ         93..235
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044826"
FT   VARIANT         363
FT                   /note="H -> N (in EPM4; no renal failure;
FT                   dbSNP:rs758857853)"
FT                   /evidence="ECO:0000269|PubMed:19454373"
FT                   /id="VAR_066744"
FT   VARIANT         471
FT                   /note="E -> G (may act as a modifier of Gaucher disease;
FT                   dbSNP:rs755903502)"
FT                   /evidence="ECO:0000269|PubMed:21796727"
FT                   /id="VAR_066745"
FT   MUTAGEN         475
FT                   /note="L->A,G,D,V: Prevents the targeting of the protein to
FT                   lysosomes."
FT                   /evidence="ECO:0000269|PubMed:7509809"
FT   MUTAGEN         475
FT                   /note="L->I: Some loss in the efficiency of targeting of
FT                   the protein to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:7509809"
FT   MUTAGEN         476
FT                   /note="I->A,V: Does not prevent the targeting of the
FT                   protein to lysosomes completely."
FT                   /evidence="ECO:0000269|PubMed:7509809"
FT   MUTAGEN         476
FT                   /note="I->D,E,G: Prevents the targeting of the protein to
FT                   lysosomes."
FT                   /evidence="ECO:0000269|PubMed:7509809"
FT   MUTAGEN         476
FT                   /note="I->L: Normal targeting of the protein to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:7509809"
FT   MUTAGEN         477
FT                   /note="R->A,E,G,K,Q: Normal targeting of the protein to
FT                   lysosomes."
FT                   /evidence="ECO:0000269|PubMed:7509809"
FT   MUTAGEN         478
FT                   /note="T->G,I,S,V: Normal targeting of the protein to
FT                   lysosomes."
FT                   /evidence="ECO:0000269|PubMed:7509809"
FT   CONFLICT        351
FT                   /note="S -> P (in Ref. 4; BAG59150)"
FT                   /evidence="ECO:0000305"
FT   HELIX           38..40
FT                   /evidence="ECO:0007829|PDB:4F7B"
FT   HELIX           48..54
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          60..70
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   HELIX           72..76
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          82..103
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   TURN            104..107
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          108..119
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   HELIX           121..123
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          124..126
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   TURN            128..130
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          132..136
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   HELIX           138..148
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   HELIX           153..162
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          167..172
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   HELIX           173..178
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   HELIX           183..191
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          197..199
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   TURN            201..204
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          213..216
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   HELIX           222..224
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          227..231
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          234..236
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          239..242
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   TURN            243..246
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          262..264
FT                   /evidence="ECO:0007829|PDB:6I2K"
FT   STRAND          266..268
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   HELIX           271..273
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          277..287
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          290..296
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   HELIX           299..302
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          303..305
FT                   /evidence="ECO:0007829|PDB:4TW2"
FT   HELIX           307..311
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   TURN            313..316
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          323..325
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   TURN            327..332
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          335..338
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   HELIX           340..342
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   HELIX           347..352
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   HELIX           360..363
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          366..370
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   TURN            371..374
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          375..389
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   HELIX           396..398
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   STRAND          404..416
FT                   /evidence="ECO:0007829|PDB:4Q4F"
FT   HELIX           419..428
FT                   /evidence="ECO:0007829|PDB:4Q4F"
SQ   SEQUENCE   478 AA;  54290 MW;  FDCF27F3BA337B2C CRC64;
     MGRCCFYTAG TLSLLLLVTS VTLLVARVFQ KAVDQSIEKK IVLRNGTEAF DSWEKPPLPV
     YTQFYFFNVT NPEEILRGET PRVEEVGPYT YRELRNKANI QFGDNGTTIS AVSNKAYVFE
     RDQSVGDPKI DLIRTLNIPV LTVIEWSQVH FLREIIEAML KAYQQKLFVT HTVDELLWGY
     KDEILSLIHV FRPDISPYFG LFYEKNGTND GDYVFLTGED SYLNFTKIVE WNGKTSLDWW
     ITDKCNMING TDGDSFHPLI TKDEVLYVFP SDFCRSVYIT FSDYESVQGL PAFRYKVPAE
     ILANTSDNAG FCIPEGNCLG SGVLNVSICK NGAPIIMSFP HFYQADERFV SAIEGMHPNQ
     EDHETFVDIN PLTGIILKAA KRFQINIYVK KLDDFVETGD IRTMVFPVMY LNESVHIDKE
     TASRLKSMIN TTLIITNIPY IIMALGVFFG LVFTWLACKG QGSMDEGTAD ERAPLIRT
//
